cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Verve Therapeutics Inc
6 own
4 watching
Current Price
$0
$0.18
(0.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,088.17M
52-Week High
52-Week High
43
52-Week Low
52-Week Low
10.7
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,088.17M
icon52-Week High43
icon52-Week Low10.7
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Verve Therapeutics Inc do?
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Verve Therapeutics Inc make?
News & Events about Verve Therapeutics Inc.
Ticker Report
1month ago
Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV Get Rating) by 58.4% during the 4th quarter, according to its most recent disclosure with the Securities Exchange Commission. The institutional investor owned 1,228,447 shares of the ...
Globe Newswire
3 months ago
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data to be Presented During an Oral Presentation at the2023 American College of Cardiologys Annual ...
PR Newswire
5 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK, Jan. 4, 2023...
Globe Newswire
5 months ago
NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verve Therapeutics, Inc. (Verve or the Company) (NASDAQ: VERV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation...
PR Newswire
5 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV PR Newswire NEW YORK, Dec. 26, 2022 NEW YORK, Dec. 26, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Verve Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Verve Therapeutics Inc shares?
plus_minus_icon
How can I buy Verve Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Verve Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Verve Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Verve Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Verve Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Verve Therapeutics Inc?
plus_minus_icon
What percentage is Verve Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Verve Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.18
(0.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00